Helen & Robert Appel Alzheimer’s Disease Research Institute

Publications

Found 229 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is P  [Clear All Filters]
2009
Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S et al..  2009.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.. Nat Neurosci. 12(7):826-8.
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM.  2009.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.. Neuron. 64(5):632-44.
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM.  2009.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.. Neuron. 64(5):632-44.
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM.  2009.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.. Neuron. 64(5):632-44.
Ringe D, Petsko GA.  2009.  What are pharmacological chaperones and why are they interesting? J Biol. 8(9):80.
2010
Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM-Y.  2010.  A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.. Am J Pathol. 177(4):1977-88.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL.  2010.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.. Nat Rev Drug Discov. 9(3):203-14.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL.  2010.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.. Nat Rev Drug Discov. 9(3):203-14.
Orr AG, Sharma A, Binder NB, Miller AH, Pearce BD.  2010.  Interleukin-1 mediates long-term hippocampal dentate granule cell loss following postnatal viral infection.. J Mol Neurosci. 41(1):89-96.
Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RLA, Kim J, May J, Tocilescu MAleksandra, Liu W, Ko HSeok et al..  2010.  PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.. Proc Natl Acad Sci U S A. 107(1):378-83.
Lewandowski NM, Ju S, Verbitsky M, Ross B, Geddie ML, Rockenstein E, Adame A, Muhammad A, Vonsattel JPaul, Ringe D et al..  2010.  Polyamine pathway contributes to the pathogenesis of Parkinson disease.. Proc Natl Acad Sci U S A. 107(39):16970-5.
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, DeMattos RB.  2010.  Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.. Clin Neuropharmacol. 33(2):67-73.
Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN.  2010.  Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis.. Proc Natl Acad Sci U S A. 107(50):21394-9.
2011
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C et al..  2011.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.. Sci Transl Med. 3(89):89ra57.
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C et al..  2011.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.. Sci Transl Med. 3(89):89ra57.
Bosco DA, LaVoie MJ, Petsko GA, Ringe D.  2011.  Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis.. Cold Spring Harb Perspect Biol. 3(10):a007500.
Paul SM.  2011.  Therapeutic antibodies for brain disorders.. Sci Transl Med. 3(84):84ps20.
Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, Bosco DA, Hayward LJ, Brown RH, Lindquist S et al..  2011.  A yeast model of FUS/TLS-dependent cytotoxicity.. PLoS Biol. 9(4):e1001052.
2012
Davies CW, Chaney J, Korbel G, Ringe D, Petsko GA, Ploegh H, Das C.  2012.  The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).. Bioorg Med Chem Lett. 22(12):3900-4.
Davies CW, Chaney J, Korbel G, Ringe D, Petsko GA, Ploegh H, Das C.  2012.  The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).. Bioorg Med Chem Lett. 22(12):3900-4.
Pranski EL, Van Sanford CD, Dalal NV, Orr AL, Karmali D, Cooper DS, Costa N, Heilman CJ, Gearing M, Lah JJ et al..  2012.  Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human brain.. Neurosci Lett. 520(1):104-9.
Hunter JM, Cirrito JR, Restivo JL, Kinley RD, Sullivan PM, Holtzman DM, Koger D, DeLong C, Lin S, Zhao L et al..  2012.  Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice.. Brain Res. 1467:120-32.
Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, M Lachenmayer L, Yue Z, Ehrlich ME, Petsko G, Ju S et al..  2012.  Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.. J Alzheimers Dis. 32(4):949-67.
Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu G-Q, Palop JJ et al..  2012.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.. Proc Natl Acad Sci U S A. 109(42):E2895-903.
Auclair JR, Somasundaran M, Green KM, Evans JE, Schiffer CA, Ringe D, Petsko GA, Agar JN.  2012.  Mass spectrometry tools for analysis of intermolecular interactions.. Methods Mol Biol. 896:387-98.